跳至主要内容
临床试验/ACTRN12622000703707
ACTRN12622000703707
尚未招募
4 期

Personalisation of anti-obesity medication selection based on Eating Behaviour Traits: examining the effect of the novel Auckland Eating Behaviour Questionnaire on weight loss in patients with obesity and type 2 diabetes

Auckland District Health Board0 个研究点目标入组 175 人2022年5月16日

概览

阶段
4 期
干预措施
未指定
疾病 / 适应症
未指定
发起方
Auckland District Health Board
入组人数
175
状态
尚未招募
最后更新
3年前

概览

简要总结

暂无简介。

注册库
who.int
开始日期
2022年5月16日
结束日期
待定
最后更新
3年前
研究类型
Interventional
性别
All

研究者

入排标准

入选标准

  • Participants, 18 \- 75 years of age, male and female, who have obesity, WHO class 1 and above (BMI 30\- 50 kg/m2\) will be invited to take part. Participants will need to be willing and able to give informed consent for participation in the study and benefit from weight loss. Only those with one dominant eating behaviour (EB) domain score of \>2 Standard deviations of the mean will be eligible to take part.
  • People in the lifestyle only group will have eating behaviours that match all possible eating behaviour traits. Patients with type 2 diabetes can be on oral hypoglycaemic medications, including metformin, sulphonylurea, pioglitazone, an SGLT2 inhibitor. Participants can have stable obesity\-related complications.

排除标准

  • Previous bariatric surgery, being diagnosed or currently suffering from a mental health problem, being prescribed psychotropic medication that could interfere or are a contraindication for the use of any one of the three weight loss medications. Other exclusion criteria include the presence of eating disorders (previously diagnosed or currently assessed) Patients with type 1 diabetes will be excluded, and treatment with a weight loss medication or a GLP1 agonist is an exclusion criterion. Patients cannot be on insulin. Exclusions are complications that would prevent the use of weight management medication, such as recent cardiovascular events, unstable angina, coronary artery bypass grafting, ischaemic stroke, myocardial infarction, percutaneous coronary intervention, epilepsy, or psychiatric disorder.

结局指标

主要结局

未指定

相似试验